Abstract
Malignant pleural mesothelioma (MPM) is an aggressive malignancy associated with asbestos exposure. It shows limited responses to all treatments. Although 20% of tumours may transiently regress after checkpoint immunotherapy1,2, predictors of response are unknown. The molecular landscape is of low complexity but recurrent lesions have not yet defined effective therapeutic targets. In order to comprehensively map genomic alterations, we combined copy-number analysis from SNP arrays with targeted sequencing of tumours from 121 patients. We found previously unrecognised deletions in the tumour suppressor RB1 in 26% of cases. These combined with CDKN2A and TP53 lesions affected the RB tumour suppressor pathway in 65% of tumours. We show here therapeutic avenues downstream of RB1 by finding micromolar half maximal inhibitory concentrations (IC50s) of PLK1, CHEK1 and Aurora Kinase inhibitors in MPM cell lines. Non-overlapping defects in Hippo pathways (RASSF7 amplification, NF2, LATS1 and LATS2 mutations) were present in 48% of tumours, accompanied by micromolar IC50s to the YAP1 inhibitor Verteporfin. Loss of a 240Kb locus containing SUFU was observed in 21% of tumours, accompanied by disordered expression of Hedgehog pathway genes. SUFU depletion was reproducibly associated with reduced transcription of T-cell and macrophage regulators, and increased transcription of the immune checkpoint inhibitor VISTA. In half of all MPM, CDKN2A deletions were accompanied by loss of Interferon Type I genes. The presence of dysregulated Hedgehog immune transcription and loss of Type I Interferons indicate novel approaches to immunotherapy.
Competing Interest Statement
SP reports honoraria from BMS, Roche, Takea, AstraZeneca, Chugai, Novartis, Pfizer, MSD, EMD Serono, Guardant Health, AbbVie, Boehringer Ingleheim, and Tesaro. All other authors have no competing interests to declare.
Funding Statement
This study was financially supported by a Libor Fund grant from the UK Department of Health, and by the Asmarley Foundation. SP acknowledges NHS funding to the Royal Marsden Hospital-Institute of Cancer Research Biomedical Research Centre. We thank Cambridge Biomedical Research Centre and Cambridge Cancer Centre.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All sequence data is being depositited with the European Genome Archive and will be made freely available following acceptance in a peer-reviewed journal